Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1189 results
June 2015
-
Press Release
Novartis presents new data at WCD demonstrating significant efficacy of Cosentyx® in patients with psoriasis of the nails, palms and soles
Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2] One third of patients… -
Press Release
Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients
74% of patients in MEASURE 2 achieved clinically significant and sustained improvement in symptoms of ankylosing spondylitis (AS) with secukinumab 150 mg after one year of treatment[1] AS is… -
Press Release
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
Data show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy[1] Recent milestones for… -
Press Release
Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs
In Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases[1],[2] Tafinlar (dabrafenib) and…
May 2015
-
Press Release
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
Final analysis of COMBI-d confirms overall survival benefit of combination therapy in patients with BRAF V600E/K mutation-positive metastatic melanoma Tafinlar and Mekinist in combination… -
Press Release
Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA
Overall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanoma New data for Zykadia® in ALK+ non-small cell… -
Press Release
Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors
Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at… -
Press Release
Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237
QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies… -
Press Release
Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLC
Zykadia (ceritinib) is the first treatment option approved for patients in Europe with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib Marketing authorization was based on…
April 2015
-
Press Release
Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLL
Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working CLL is the most… -
Press Release
Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio
Continuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)… -
Press Release
Novartis a affiché, au T1[1], une forte progression de ses ventes (tcc), une hausse importante de sa marge (tcc) et une innovation très dynamique; avec un portefeuille désormais mieux ciblé
Ventes, résultat opérationnel core[2] et BPA core (tcc[2]) des activités poursuivies[1] en hausse au T1 Chiffre d'affaires net s'élevant à USD 11,9 milliards (-7%, +3% tcc)]2] Résultat…